Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta‐analysis

Abstract

BackgroundAlzheimer’s disease (AD) is a globally prevalent neurodegenerative disease, clinically characterized by progressive memory loss and gradual impairment of cognitive functions. Mesenchymal stem cells (MSCs) transplantation has been considered a possible therapeutic method for Alzheimer’s disease (AD). However, no quantitative data synthesis of MSC therapy for AD exists. We conducted a systematic review and meta‐analysis to study the effects of MSCs on cognitive deficits in animal models of AD.MethodsWe identified eligible studies published from January 1980 to January 2017 by searching four electronic databases (PubMed, MEDLINE, EMBASE, CNKI). The endpoint was the effects of MSCs on cognitive performance evaluated by the Morris water maze (MWM) test including escape latency, and/or number of platform crossing, and/or time in the target quadrant.ResultsNine preclinical studies incorporating 225 animals with AD were included for the meta‐analysis. The studies indicated that MSC‐based treatment significantly improved the learning function through measurements of the escape latency (SMD = −0.99, 95% CI = −1.33 to −0.64, p < .00001). Additionally, we observed that transplantation of MSCs significantly increased the number of platform crossing in six experiments (SMD = 0.78, 95% CI = 0.43 to 1.13, p < .0001). What’s more, the times in the target quadrant were increased in five studies indicated that transplantation of MSCs could ameliorate the cognitive impairments (SMD = 1.06, 95% CI = 0.46 to 1.67, p = .0005).ConclusionsThis study showed that MSC transplantation could reduce cognitive deficits in AD models. These findings support the further studies to translate MSCs in the treatment of AD in humans

Bone marrow mesenchymal stem cells and their derived exosomes resolve doxorubicin-induced chemobrain: critical role of their miRNA cargo

“…Ameliorative effects of BMSCs and BMSCs-Exo were previously assessed in different cognitive deficits models [ 29 , 30 , 56 ]. Increasing evidences proved that BMSCs can successfully pass the blood-brain barrier (BBB) to reduce the injured brain area which subsequently leads to behavioral improvement [ 57 ].…”

“…for 4 consecutive weeks followed by a single intravenous injection of (1 × 10 6 ) BMSCs that was given 48 h after the last DOX dose. This dose range was chosen in accordance with doses used in various in vivo studies of BMSCs in different cognitive impairment diseases [ 26 – 29 ].…”

Intracerebral Injection of Extracellular Vesicles from Mesenchymal Stem Cells Exerts Reduced Aβ Plaque Burden in Early Stages of a Preclinical Model of Alzheimer’s Disease

“…Cell therapy is becoming a new reality for many diseases. Due to the plasticity and multifaceted features of stem cells, recent studies have also focused on their possible exploitation in AD [6,7,8]. Multipotent bone marrow mesenchymal stem cells (BM-MSCs) represent a heterogeneous subset of stromal cells.…”

Pro-inflammatory Cytokine GM-CSF Improves Learning/Memory and Brain Pathology in Dp16 Down Syndrome Mice and Improves Learning/Memory in Wild-Type Mice

“…In addition to its effects on NSCs, GM-CSF has been shown to mobilize mesenchymal stem cells (MSCs) from the bone marrow and to enhance their differentiation and migration in response to injury (109,110). MSCs have been reported to have beneficial cognitive and regenerative effects and are being investigated as potential positive effectors in several neurological disorders, including AD, PD, and spinal cord injury (111)(112)(113)(114)(115)(116)(117).…”